News | May 14, 2024
Bayer Q1 2024 net income drops 8.2% to € 2 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
2024 full-year revenue guidance raised by US$ 2 billion
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Subscribe To Our Newsletter & Stay Updated
